If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter ...

) has been revised to $88.30 / share. This is a decrease of 13.54% from the prior estimate of $102.13 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...

What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. The retreat in oil prices provided ...

BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.

Looking into the current session, DexCom Inc. (NASDAQ:DXCM) shares are trading at $69.95, after a 0.09% increase. Moreover, over the past month, the stock spiked by 2.13%, but in the past year, fell ...

Without a specific news headline driving the move, DexCom (DXCM) sits at a recent close of US$70.69, leaving investors weighing its continuous glucose monitoring business against recent share price ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...